Printer Friendly

Oxygen Biotherapeutics, Inc. files patent application for emergency heart attack treatment device.

Oxygen Biotherapeutics, Inc. (Durham, NC) has submitted a patent application for a new invention that uses Oxycyte perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The invention provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be easily used by a person who has suffered a heart attack or stroke, but is still conscious, without the assistance of another. It may also be used easily by someone who cannot adequately perform CPR in order to assist someone who is unconscious.

By safely combining Oxycyte and oxygen in a device without pressure, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim's lungs an oxygen load that is 50 times greater than what the same volume of blood is able to carry. The concept of this invention is to administer oxygen-enriched Oxycyte through the lungs to reach oxygen-deprived tissues even when circulation is obstructed and/or a person has stopped breathing.

"This exciting new invention builds on our other intellectual property and gives us a way to leverage even greater value from our key product, Oxycyte. We've already named the invention Vitavent. Ultimately, I see this device being sold over the counter and present wherever there is a defibrillator as well as in any home where there is concern about a potential heart attack or stroke for a loved one," said Chris Stern, company chairman and CEO. "We are already working on the market prototypes and intend to file a new device application with the FDA as soon as possible."

"With Vitavent, we now have a fourth pillar for our business strategy. It joins our cosmetic application, Dermacyte, which we intend to launch in Q4; Wundecyte, our wound care device and application; and our clinical compound Oxycyte, which is now in a Phase II-b clinical trial for Traumatic Brain Injury," said Stern.

Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications.

Oxygen Biotherapeutics, Inc.

+1-619-795-2345

www.oxybiomed.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2009
Words:459
Previous Article:Encouraging HIV/AIDS vaccine trial results support GeoVax strategy.
Next Article:United States District Court upholds validity of Lilly's Evista patents through 2014.
Topics:


Related Articles
Oxygen Biotherapeutics, Inc. Establishes Warfighter Division.
Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel.
Oxygen Biotherapeutics, Inc. Submits Orphan Drug Application for Oxycyte.
Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute...
Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement.
Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants.
Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009.
Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland.
GENova files patent for new breast cancer treatment.
Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters